Skip to content

Immix Biopharma, Inc. IMMX Income taxes receivable

Income taxes receivable at other companies

Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
$109.17M

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxReceivable.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s income taxes receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s income taxes receivable?
Immix Biopharma, Inc. (IMMX) reported income taxes receivable of $0 in Q1 2026.
What is the long-term trend for Immix Biopharma, Inc.'s income taxes receivable?
Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s income taxes receivable has grown at a -100.0% compound annual growth rate (CAGR), from $127.44K to $0.
What does income taxes receivable mean?
Income tax refunds or overpayments expected from tax authorities, including estimated tax prepayments in excess of actual liability.